Biotech Values

[jq1234]

If there was any legitimate concern regarding its effect on the cardiovascular system, surely someone would have noticed it before.

That's not a convincing argument. Listen to AMLN cc when CEO said FDA raised the QT issue before, but AMLN didn't know it was an approvability issue.

As the business of healthcare becomes bogged down by ineffective and expensive layers of bureaucracy, to the point that they exceed the benefits of finding new treatments, the whole system runs the danger of collapsing.

Please don't raise Bydureon to the larger issue of overall survival of healthcare system. Everyone tried to raise this issue when their drug isn't approved. Healthcare system is a lot more complex than this.

Bydureon is the first diabetes drug the FDA will have a chance to approve which will offer benefits that are far superior to any existing diabetes medication currently being sold and that has a well documented safety profile that is low in risks.

How could anyone make this claim? Based on what?

For those that would make it seem that Bydureon is the long awaited cure for diabetes...please join us in reality. Once- weekly dosing is this product's biggest advantage and that hardly makes it a product that patients can't live without until 2012. Other products with once-weekly[or once-daily] formulations haven't exactly lit the market on fire or even improved compliance. Many endocrinologists and educators are skeptical since diabetes is hardly a once weekly disease. Patients need to be tending to their disease on a daily basis, because it's with them every day.

At least someone put this in perspective.